Abstract Details

Title Development and Description of the International RBD Study Group RBD Symptom Severity Scale

Topic Sleep

Presentation(s) P2 - Poster Session 2 (11:45 AM-12:45 PM)

Poster/Presentation
Number 1-004

Objective To describe the design and development of the REM sleep behavior disorder Symptom Severity Scale (RBD-SSS), by the International RBD Study Group, for use in clinical settings as well as clinical trials.

Background As clinical trials for RBD advance, it will be imperative to have reliable measures to track change over time. Currently, there is no standard scale to assess severity of RBD symptoms in the home environment.

Design/Methods In 2016, an initial draft of the RBD-SSS was presented to the annual International RBD study group meeting (by RP). Separate versions were created for patients and for their bed partners. Over the subsequent 2 years, revisions were made, and validation testing started in 2018 (by MLF) and in 2020 as part of the North American Prodromal Synucleinopathy Cohort (by PC and JL, see accompanying abstract).

Results The patient and bedpartner versions of the scale consist of 3 core components, namely vocalizations, body movements, and injury. In the patient version, a 4^th component (dream content/nightmares) is also assessed. All components use the timescale of the previous month. Each component queries both the frequency of the behavior: never, rarely (<1/week), occasionally (1-2/week), frequently (3-7/week, or very frequently (>7/week, i.e., more than once per night) and the severity/consequence of the behavior (none, mild, moderate, or severe). Additional questions (not scored) assess a clinical global impression of severity, whether there is a regular bed partner, and if not, whether RBD symptoms required patients to sleep apart.

Conclusions The RBD Symptom Severity Scale provides a means to test the severity of RBD symptoms in clinical settings and for clinical trials. Validation of the scale is required, and is currently in final stages.

Authors/Disclosures
Ronald Postuma, MD (Montreal General Hospital) PRESENTER	Dr. Postuma has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche, Biogen, Takeda, Theranexus, GE, Jazz, Curasen, Paladin, Inception Sciences, Phytopharmics, Vaxxinity, Merck. Dr. Postuma has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen/Partners. The institution of Dr. Postuma has received research support from CIHR, Weston Foundation, Webster Foundation, Roche, MJFF, Parkinson Canada, FRSQ, NIH.
	No disclosure on file
	No disclosure on file
Parichita Choudhury, MD (Banner Sun Health Research Institute)	The institution of Dr. Choudhury has received research support from Lewy Body Dementia Association. The institution of Dr. Choudhury has received research support from Arizona Alzheimer's Consortium.
Joyce K. Lee-Iannotti, MD, FAAN (Barrow's Neurological Institute)	Dr. Lee-Iannotti has nothing to disclose.

��ɫ��

��ɫ��